HCW Biologics Inc. announced positive preliminary data from the first two dose cohorts of its dose-escalating Phase 1 clinical trial for HCW9302, an IL-2 based immunotherapeutic for patients with alopecia areata. The results showed a positive clinical response and a well-tolerated safety profile after a single dose.
Key Details
- Positive Efficacy Signal: All three participants in the second dose cohort (3 micrograms/kg) demonstrated a ≥25% reduction in Severity of Alopecia Tool (SALT) scores at four and/or nine weeks post-treatment.
- Favorable Safety Profile: The treatment was well tolerated with no dose-limiting toxicities or serious adverse events commonly associated with IL-2 therapy, such as capillary leak or cytokine release syndrome.
- Next Steps: The trial is progressing to the third dose cohort (8 micrograms/kg), and the company projects to establish the Recommended Phase 2 Dose by the end of 2026.